Synthon B.V., Synthon Hispania S.L.
PolandAll drugs from this manufacturer
-
This medicine is intended for adult men with prostate cancer that has metastasized to other parts of the body. It works by inhibiting the production of testosterone, which can slow the growth of the tumor.
Dosage form: tablets
Active substance Dosage abiraterone acetate 250 mg ATC: L02BX03
-
The medicine is intended for adult men with prostate cancer that has metastasized to other parts of the body. It works by inhibiting the production of testosterone, which can slow the growth of the tumor.
Dosage form: tablets, film-coated
Active substance Dosage abiraterone acetate 500 mg ATC: L02BX03
-
The medicine is intended for adult men with prostate cancer that has metastasized to other parts of the body. It works by inhibiting the production of testosterone, which can slow the growth of the tumor.
Dosage form: tablets, film-coated
Active substance Dosage abiraterone acetate 500 mg ATC: L02BX03
-
This medicine is intended for adult men with prostate cancer that has spread to other parts of the body. It works by inhibiting the production of testosterone, which can slow the growth of the tumor.
Dosage form: tablets, film-coated
Active substance Dosage abiraterone acetate 500 mg ATC: L02BX03
-
This medicine is used to treat essential thrombocythemia. It helps reduce the production of platelets by the bone marrow, bringing their number down to a more normal level.
Dosage form: capsules, hard
Active substance Dosage anagrelide 0.5 mg ATC: L01XX35
-
This medicine is used to treat essential thrombocythemia. It helps to reduce the production of platelets by the bone marrow, which reduces their number in the blood to a normal level.
Dosage form: capsules, hard
Active substance Dosage anagrelide 1 mg ATC: L01XX35
-
This medicine is used to treat essential thrombocythemia. It helps to reduce the number of platelets by limiting their production by the bone marrow, which prevents serious circulatory and clotting disorders.
Dosage form: capsules, hard
Active substance Dosage anagrelide 0.5 mg ATC: L01XX35
-
This medicine is used to treat essential thrombocythemia. It helps to reduce the number of platelets by limiting their production by the bone marrow, which prevents serious circulatory and clotting disorders.
Dosage form: capsules, hard
Active substance Dosage anagrelide 1 mg ATC: L01XX35
-
The drug is used in the treatment of schizophrenia in patients who do not respond to other antipsychotic medications. It is also used to treat severe disturbances in thinking, emotion, and behavior in individuals with Parkinson's disease who do not respond to other treatments.
Dosage form: tablets, dispersible in the oral cavity
Active substance Dosage clozapine 12.5 mg ATC: N05AH02
-
The medicine is used in the treatment of patients with schizophrenia for whom other antipsychotic drugs have not been effective or have caused severe side effects. It is also used in the treatment of severe disturbances in thinking, emotion, and behavior in people with Parkinson's disease who do not respond to other treatments.
Dosage form: tablets, dispersible in the oral cavity
Active substance Dosage clozapine 25 mg ATC: N05AH02
-
The medicine is used in the treatment of schizophrenia in patients who do not respond to other antipsychotic drugs. It is also used to treat severe disturbances in thinking, emotion, and behavior in individuals with Parkinson's disease, where other treatment methods have not been effective.
Dosage form: tablets, dispersible in the oral cavity
Active substance Dosage clozapine 100 mg ATC: N05AH02
-
The medicine is used to treat patients with schizophrenia who have not responded to other antipsychotic medications or who have experienced severe side effects. It is also used to treat severe disturbances in thinking, emotion, and behavior in individuals with Parkinson's disease who do not respond to other treatments.
Dosage form: tablets, dispersible in the oral cavity
Active substance Dosage clozapine 200 mg ATC: N05AH02
-
The medicine is used in adults to relieve symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
Dosage form: capsules, hard
Active substance Dosage celecoxib 100 mg ATC: M01AH01
-
The medicine is used in adults to relieve the symptoms of rheumatoid arthritis, osteoarthritis, and ankylosing spondylitis.
Dosage form: capsules, hard
Active substance Dosage celecoxib 200 mg ATC: M01AH01
-
The medicine is used in adults to treat a certain type of chronic heart failure. This occurs when the heart is too weak to pump an adequate amount of blood to the lungs and the rest of the body.
Dosage form: tablets, film-coated
Active substance Dosage sacubitril sodium 25.6 mg valsartan sodium salt 28.3 mg ATC: C09DX04
-
The medicine is used in adults to treat a certain type of chronic heart failure. This occurs when the heart is too weak to pump an adequate amount of blood to the lungs and the rest of the body.
Dosage form: tablets, film-coated
Active substance Dosage sacubitril sodium 51.2 mg valsartan sodium 56.6 mg ATC: C09DX04
-
The medicine is used in adults for the treatment of a certain type of chronic heart failure. This occurs when the heart is too weak to pump an adequate amount of blood to the lungs and the rest of the body.
Dosage form: tablets, film-coated
Active substance Dosage sacubitril sodium 102.4 mg valsartan sodium salt 113.2 mg ATC: C09DX04
-
The medicine is used for the treatment of acute lymphoblastic leukemia (ALL) in adults, adolescents, and children over 1 year of age, and for the treatment of chronic myeloid leukemia (CML) in adults, adolescents, and children over 1 year of age. It is also used in adults for the lymphoblastoid blast crisis of CML, if previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 20 mg ATC: L01EA02
-
The medicine is used for the treatment of acute lymphoblastic leukaemia (ALL) in adults, adolescents and children over 1 year of age, and for the treatment of chronic myeloid leukaemia (CML) in adults, adolescents and children over 1 year of age, as well as in the lymphoblastoid blast crisis of CML in adults.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 50 mg ATC: L01EA02
-
The medicine is used to treat acute lymphoblastic leukemia (ALL) in adults, adolescents, and children over 1 year of age, and to treat chronic myeloid leukemia (CML) in adults, adolescents, and children over 1 year of age. It is also used in adults for the lymphoblastoid blast crisis of CML if previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 70 mg ATC: L01EA02
-
The medicine is used for the treatment of acute lymphoblastic leukemia (ALL) in adults, adolescents, and children over 1 year of age, and for the treatment of chronic myeloid leukemia (CML) in adults, adolescents, and children over 1 year of age, as well as in the lymphoblastoid blast crisis of CML in adults.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 80 mg ATC: L01EA02
-
This medicine is used to treat acute lymphoblastic leukemia (ALL) and chronic myeloid leukemia (CML) in adults, adolescents, and children aged 1 year and older. It inhibits the growth of cancer cells.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 100 mg ATC: L01EA02
-
This medicine is used to treat acute lymphoblastic leukemia (ALL) in adults, adolescents, and children over 1 year of age, and to treat chronic myeloid leukemia (CML) in adults, adolescents, and children over 1 year of age, as well as in the lymphoblastoid blast crisis of CML in adults.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 140 mg ATC: L01EA02
-
This medicine is used to treat chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and to treat acute lymphoblastic leukemia in adults, adolescents, and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of chronic myeloid leukemia in whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 20 mg ATC: L01EA02
-
This medicine is used to treat chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age) and to treat Philadelphia chromosome-positive (Ph+) acute lymphoblastic leukemia (ALL) in adults, adolescents, and children (from 1 year of age), as well as in the lymphoblastic blast crisis of myeloid leukemia in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 50 mg ATC: L01EA02
-
The medicine is used to treat chronic myeloid leukemia in adults, adolescents, and children (from 1 year of age), as well as to treat acute lymphoblastic leukemia in adults, adolescents, and children (from 1 year of age), and in the lymphoblastic blast crisis in adults for whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 80 mg ATC: L01EA02
-
This medicine is used to treat chronic myeloid leukemia in adults, adolescents and children (from 1 year of age) and to treat acute lymphoblastic leukemia in adults, adolescents and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of chronic myeloid leukemia, in whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 100 mg ATC: L01EA02
-
This medicine is used to treat chronic myeloid leukemia in adults, adolescents and children (from 1 year of age) and to treat acute lymphoblastic leukemia in adults, adolescents and children (from 1 year of age). It is also used in adults for the lymphoblastic blast crisis of chronic myeloid leukemia, in whom previous treatment has not been effective.
Dosage form: tablets, film-coated
Active substance Dosage dasatinib 140 mg ATC: L01EA02
-
The medicine is intended for the symptomatic treatment of mild to moderate dementia in Alzheimer's disease in adults.
Dosage form: tablets, film-coated
Active substance Dosage donepezil hydrochloride monohydrate 5 mg ATC: N06DA02
-
The medicine is intended for the symptomatic treatment of mild to moderate dementia in Alzheimer's disease in adults.
Dosage form: tablets, film-coated
Active substance Dosage donepezil hydrochloride monohydrate 10 mg ATC: N06DA02
-
This medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (who have not responded to other medicines) and in adults with hepatitis C virus infection who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
This medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (who have not responded to other medicines) and in adults with hepatitis C virus infection who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used to increase the number of platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (who have not responded to other medicines) and in adults with a low platelet count due to hepatitis C virus infection.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 12.5 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia (in patients for whom other medicines have not worked) and in adults with hepatitis C virus infection who have experienced difficulties due to adverse effects during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is used to treat immune thrombocytopenia in individuals over 1 year of age for whom other medicines have not worked, and in adults with hepatitis C who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used to increase the number of platelets. It is intended for the treatment of immune thrombocytopenia (in patients for whom other medicines have not worked) and in adults with hepatitis C virus infection who have a low platelet count that makes antiviral treatment difficult.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age for whom other medicines have not worked, and in adults with hepatitis C who have experienced difficulties due to adverse effects during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 12.5 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia (in individuals over 1 year of age for whom other medicines have not worked) and in adults with hepatitis C who have experienced a low platelet count during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
The medicine is used to increase the number of platelets in the blood. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (when other medicines have not worked) and in adults with hepatitis C virus infection who have experienced difficulties due to adverse effects during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia (in individuals over 1 year of age for whom other medicines have not worked) and in adults with hepatitis C who have experienced a low platelet count during interferon treatment.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg ATC: B02BX05
-
This medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia (in individuals over 1 year of age for whom other medicines have not worked) and in adults with a low platelet count caused by hepatitis C virus infection.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 12.5 mg ATC: B02BX05
-
This medicine is used to increase the number of blood platelets. It is prescribed for the treatment of immune thrombocytopenia (in individuals over 1 year of age for whom other medicines have not worked) and in adults with a low platelet count due to hepatitis C virus infection.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (who have not responded to other medicines) and in adults with hepatitis C virus who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia (in individuals over 1 year of age for whom other medicines have not worked) and in adults with a low platelet count due to hepatitis C virus infection.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 75 mg ATC: B02BX05
-
The medicine is used to increase the number of blood platelets. It is intended for the treatment of immune thrombocytopenia in individuals over 1 year of age (when other medicines have not worked) and in adults with hepatitis C virus infection who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 25 mg ATC: B02BX05
-
The medicine is used to increase the number of platelets. It is intended for the treatment of immune thrombocytopenia (in people for whom other medicines have not worked) and in adults with hepatitis C virus infection who have a low platelet count.
Dosage form: tablets, film-coated
Active substance Dosage eltrombopag 50 mg ATC: B02BX05
-
The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (when the cancer cells have specific EGFR mutations) and in the treatment of metastatic pancreatic cancer (in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02
-
The medicine is used in adult patients for the treatment of advanced non-small cell lung cancer (when the cancer cells have specific EGFR mutations) or in cases where previous chemotherapy has not been effective. It may also be used in the treatment of metastatic pancreatic cancer in combination with gemcitabine.
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 100 mg ATC: L01EB02
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (provided specific EGFR mutations are present) and for patients with metastatic pancreatic cancer (in which case it is used in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 150 mg ATC: L01EB02
-
The medicine is intended for adult patients with advanced non-small cell lung cancer (as first-line treatment or when the disease has not responded to chemotherapy) and in the case of metastatic pancreatic cancer (used in combination with gemcitabine).
Dosage form: tablets, film-coated
Active substance Dosage erlotinib 25 mg ATC: L01EB02